Feedback on patients treated with highly intensity statin/ezetimibe combinations. Do we need to go further? Dyslipidemia Symposia & Webinars Feedback on patients treated with highly intensity statin/ezetimibe combinations. Do we need to go further? Alberto Zambon and Leopoldo Perez de Isla conduct a concise analysis about choices around monotherapy and combination therapy in dyslipidemia.
Statin/ezetimibe combinations: data and evidence, for which patients Dyslipidemia Symposia & Webinars Statin/ezetimibe combinations: data and evidence, for which patients Alberto Zambon presents data and evidence on efficacy of LDL-lowering therapies, from the IMPROVE_IT and Jupier trials.
How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations. Dyslipidemia Symposia & Webinars How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations. Leopoldo Perez de Isla discusses 2 interesting approaches to the updated version of ESC guidelines.
Broader usage of combinations in daily clinical practice: what benefits for patients? Dyslipidemia Symposia & Webinars Broader usage of combinations in daily clinical practice: what benefits for patients? Alberto Zambon discusses in detail the use of combinations therapies to manage LDL-C.
What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term? Dyslipidemia Symposia & Webinars What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term? Interesting evidence by Dr. Pérez de Isla on lowering LDL-C, focused on 3 main aspects: Get it low – Get it soon – Get it forever.
ESC Guidelines 2019: what has changed? Dyslipidemia Symposia & Webinars ESC Guidelines 2019: what has changed? Introduction by Alberto Zambon to treatment goals, recommendations, and the algorithm of the updated ESC guidelines.
